Management of cutaneous side effects of EGFR inhibitors: Recommendations from a German expert panel for the primary treating physician;Management kutaner nebenwirkungen von EGFR-inhibitoren: Empfehlungen eines Deutschen expertengremiums für den primär behandelnden arzt

JDDG - Journal of the German Society of Dermatology

Volumn 9, Issue 3, 2011, Pages 195-202

  Gutzmer, Ralf ^a   Becker, Jürgen C ^b   Enk, Alexander ^c   Garbe, Claus ^d   Hauschild, Axel ^e   Leverkus, Martin ^f   Reimer, Georg ^g   Treudler, Regina ^h   Tsianakas, Athanasios ⁱ   Ulrich, Claas ^j   Wollenberg, Andreas ^k   Homey, Bernhard ^l  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g Praxis für Dermatologie und Allergologie   (Germany)

^h UNIVERSITY OF LEIPZIG   (Germany)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

Cutaneous side effects; EGFR; Papulopustular exanthema

Indexed keywords

AZELAIC ACID; BECLOMETASONE; CETUXIMAB; CICLOPIROX; CICLOPIROXOLAMINE; CLOTRIMAZOLE; COLLAGEN; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUCLOXACILLIN; GEFITINIB; HYDROCORTISONE; HYDROCORTISONE BUTYRATE; KETOCONAZOLE; LAPATINIB; LIDOCAINE; MENADIONE; METHYLPREDNISOLONE ACEPONATE; METRONIDAZOLE; MINOCYCLINE; NADIFLOXACIN; OCTENIDINE; PANITUMUMAB; PERMETHRIN; PIMECROLIMUS; SUNSCREEN; TAZAROTENE; TETRACYCLINE; UNINDEXED DRUG;

ADVANCED CANCER; ANTIBIOTIC PROPHYLAXIS; BACTERIAL SUPERINFECTION; COLORECTAL CANCER; COLORECTAL CARCINOMA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG WITHDRAWAL; FACE; GRANULATION TISSUE; HAIR DISEASE; HEAD AND NECK CARCINOMA; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; PANCREAS CARCINOMA; PAPULOPUSTULAR EXANTHEMA; PARONYCHIA; PATHOPHYSIOLOGY; PERIORAL DERMATITIS; PHYSICIAN; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SEBORRHEIC DERMATITIS; SKIN CARE; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; TRICHOMEGALY; TRUNK; XEROSIS;

EID: 79952208752     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2010.07561.x     Document Type: Review

References (36)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37. (Pubitemid 33674041)
3. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Hölscher AH, Danenberg PV. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-5. (Pubitemid 32994816)
4. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59 (2 Suppl): 21-6. (Pubitemid 38610223)
5. Wollenberg A, Kroth J, Hauschild A, Dirschka T. Hautreaktionen unter EGFR-Inhibitoren - Klinik und Management. Dtsch Med Wochenschr 2010; 135: 149-54.
6. Treudler R. New drug therapies and their effect on the skin. J Dtsch Dermatol Ges 2009; 7: 623-37.
7. Joshi SS, Ortiz S, Witherspoon JN, Radermaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME. Effects of epidermal growth factor receptor inhibitor- induced dermatologic toxicities on quality of life. Cancer 2010; 116: 3916-23.
8. Nanney LB, Stoscheck CM, King LE Jr. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990; 94: 742-8. (Pubitemid 20184371)
9. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10: 505-10.
10. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol 2009; 4: 107-19.
11. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803-12. (Pubitemid 44450468)
12. Han SS, Lee M, Park GH, Bang SH, Kang YK, Kim TW, Lee JL, Chang HM, Ryu MH. Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. Br J Dermatol 2010; 162: 371-9.
13. Eames T, Kroth J, Flaig MJ, Ruzicka T, Wollenberg A. Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy. Acta Derm Venerol 2010; 90: 202-3.
14. Wollenberg A, Moosmann N, Klein E, Katzer K. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 2008; 17: 790-2.
15. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 3913-21. (Pubitemid 47037599)
16. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-6. (Pubitemid 46972777)
17. van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Cosaert J. Rash as a marker for the efficacy of gemcitabine plus Erlotinib-based therapy in pancreatic cancer: Results from the AViTA study. ASCO Gastrointestinal Cancers Symposium 2009, Abstr. 117.
18. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-8.
19. O'Byrne K, Rodrigues Pereira J, von Pawel J, Szczesna A, Waller C, Barrios C, Gatzemeier U, Celik L, Stroh C, Pirker R. Molecular and clinical biomarkers of outcome with cetuximab: Data from the phase III FLEX study in non-small cell lung cancer (NSCLC). ECCO 15-ESMO 34; 2009: Abstr./ Poster 9.160.
20. Rougier P, Stroiakovski D, Köhne C, Chang Chien C, Lim R, Pintér T, Bodoky G, Stroh C, J. Nippgen, van Cutsem E. Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer (mCRC): Updated survival data and influence of KRAS status on outcome in the CRYSTAL study. ASCO GI 2009; Abstr. 443.
21. Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009; 115: 1544-54.
22. Dainichi T, Tanaka M, Tsuruta N, Furue M, Noda K. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inibitor of epidermal growth factor receptor. Dermatology 2003; 207: 324-5. (Pubitemid 37329208)
23. Fox LP. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 2007; 56: 460-5. (Pubitemid 46273839)
24. Eames T, Grabein B, Kroth J, Wollenberg A. Microbiological analysis of epidermal growth factor receptor inihibitor therapy associated paronychia. J Eur Acad Dermatol Venereol 2010; 24: 958-60.
25. Bouché O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005; 16: 1711-2. (Pubitemid 41510151)
26. Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 2003; 42: 345-6. (Pubitemid 36851154)
27. Alexandrescu DT, Kauffman CL, Dasanu CA. Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Dermatol Online J 2009; 15(3): 4.
28. Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi E, Crinò L, De Marinis F, Di Pietro FA, Grossi F, Innocenzi D, Micali G, Piantedosi FV, Scartozzi M. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Oncol Hematol 2008; 66: 155-62.
29. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19: 142-9.
30. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009; 16: 16-26.
31. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113: 847-53.
32. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25: 5390-6. (Pubitemid 350232214)
33. Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, Halpern AC. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009; 61: 614-20.
34. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 1351-7.
35. Deplanque G, Chavaillon J, Vergnenegre A, Falchero L, Fraboulet G, Gervais R, Taviot B, Souquet PJ, Robert C, Chosidow O. CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. J Clin Oncol 2010; 28: 15s (Suppl; Abstr. 9019).
36. Katzer K, Tietze J, Klein E, Heinemann V, Ruzicka T, Wollenberg A. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFRinhibitor cetuximab - A report of 29 patients. Eur J Dermat 2010; 20: 82-4.